Special webinar on NIH Other Support offered via Zoom
Scheduled for May 11, 2021 at 1:00CT
Topic: Writing NIH Other Support Pages
NIH Requires Changes as of January 25, 2022
Please register in advance for this meeting:
https://zoom.us/meeting/register/tJIvduutqDkuHNWeMerHMJ1Wxm2TVrGwqLJt (corrected link)
After registering, you will receive a confirmation email containing information about joining the meeting.
OUHSC will start implementing this process on July 1, 2021.
OK-INBRE REQUEST FOR APPLICATIONS FOR RESEARCH PROJECTS
The Oklahoma IDeA Network of Biomedical Research Excellence (OK-INBRE) is requesting applications for research projects from full-time, tenure track faculty (or equivalent) at the University of Oklahoma Health Sciences Center (OUHSC) or the Oklahoma Medical Research Foundation (OMRF). OK-INBRE will fund four Research Project Investigator (RPI) Awards with a start date of November 1, 2021 and an end date of April 30, 2024. Funding for awards is anticipated to be $100,000 in direct costs per year. Applications must align with one of the OK-INBRE research themes of 1) Cancer, 2) Developmental Biology, or 3) Infectious Diseases. The application deadline is 5pm on August 13, 2021. Please see the attached funding opportunity announcement for details. Information can also be found on the OK-INBRE website at Funding Opportunities for OUHSC and OMRF. Questions regarding this OK-INBRE opportunity can be sent to Dawn Hammon (firstname.lastname@example.org) or Darrin Akins (email@example.com).
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email firstname.lastname@example.org or email@example.com).
- Company (requested anonymity) is seeking to engage with academic partners to develop lymphatic-based disease solutions – focusing on minimally invasive treatments. Submission entails a 1-pg non-confidential summary of technology (deadline 5/7/2021).
- Reckitt is seeking to engage with academic partners to 1) develop approaches to enhance oral drug delivery into the pharyngeal, esophageal, or colon; 2) enhance the safety of OTC medications, or 3) develop natural/non-medicated solutions for upper and lower GI conditions, sore throat, cough, cold, flu, and pain. Submission entails a 1-pg non-confidential summary of technology (deadline 5/27/2021)
- Pfizer’s Centers for Therapeutic Innovation (https://www.pfizercti.com) is seeking collaborative proposals for developing novel therapeutic targets with application in 1) oncology: tumor targeted, immuno-oncology, cancer vaccines; 2) internal medicine: obesity/cachexia, heart failure, diabetic/CKD, NASH/T2D; 3) inflammation and immunology: rheumatology, gastroenterology, medical derm; or 4) rare disease: cardiology, neuro-musc., metabolic, hematology. Preference is for novel biological targets supported by in vivo and in vitro models, enabling genetics and mechanistic insights, translational biochemical or cellular assay and biomarkers. Out of scope: drug repurposing, standalone biomarker assays/platforms, medical devices, cell-based therapies. Proposal template available upon request (submission deadline 6/18/21).
Join the Alzheimer’s Drug Discovery Foundation (ADDF) for their 15th Annual Drug Discovery for Neurodegeneration Workshop. This will be held virtually on May 4 – 5, 2021. Browse through the exciting program to see session titles and speaker bios for the internationally recognized leaders in neuroscience who will be sharing their experiences from different stages of the drug discovery pipeline. The program features guest lectures, Q&A sessions and panel discussions, complemented by several short presentations selected from submitted application. This year, Harrington Discovery Institute’s Director of Neurotherapeutics, Andrew A. Pieper, MD, PhD, will be chairing a session, during which 2016 ADDF-Harrington scholar, Travis Dunckley, PhD, Arizona State University, and HDI Therapeutics Development Advisor, Siew Peng Ho, PhD, will give a lecture on ASOs. Free registration is available now on the website.
Reopening of Research at OUHSC
The Phase Two Return to Research Plan has allowed for the successful, gradual, and phased reopening of bench laboratory research. One key component of Phase Two was the population density limit of one researcher for every 250 sq ft of laboratory space. This conservative population density was established to minimize COVID-19 risk in the research environment while the Vice President for Research (VPR) office evaluated the effectiveness of the reopening plan. Based upon that review and the current COVID-19 guidance and data, the VPR office, in consultation with the Specific Pathogens Preparedness Operations/Emergency Operations Exec team, has determined that effective Tuesday, June 1, bench laboratory research areas may increase capacity to the extent that allows a 3-foot social between all personnel. In accordance with campus COVID-19 policies, masks must be worn at all times in indoor facilities, including labs. If you are uncertain whether your lab can accommodate your personnel numbers observing the required 3-foot social distancing requirement, please contact Chris Tucker in Operations to request your space be measured for this new COVID capacity. Also in accordance with campus policy, labs remain closed to K-12 students but open to undergraduates, graduates, and post-docs from any institution, provided the following are observed:
- non-HSC individuals will complete the online visitor screening tool prior to their first day on campus
- all individuals will complete the HSC online COVID-19 training module in OnPoint, using their HSC credentials
- all individuals will be required to show proof of a negative COVID test (within past 48 hours) or documentation of COVID vaccination, if required based on screening results
- all individuals will strongly encouraged to be vaccinated against COVID-19
- all individuals will be informed that they must comply with the HSC COVID-19 Response Plan
With these changes, we are retiring the Return to Research Plan and will refer to the OUHSC COVID Response Plan for COVID protocols. If you identify any gaps that this leaves, please email firstname.lastname@example.org. It is expected that all personnel will adhere to the requirements in the
OUHSC COVID-19 Response Plan.
UPDATE: HSC COVID-19 Response Plan - effective April 13, 2021
This revised Plan (https://www.ouhsc.edu/coronavirus) includes some minor clarifications to current HSC COVID-19 protocols, as well as some more substantive revisions, including:
Section I Telecommuting – Telecommuting in response to COVID-19 is being phased out.
- By June 2, 2021, at least 50% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By July 1, 2021, at least 75% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By August 1, 2021, 100% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus
Section III Social Distancing and Gatherings – Effective June 1, social distance measurement will be 3 feet, except in patient care and eating areas which remain at 6 feet.
-This information is included in the Response Plan now for planning purposes. Our medical and public health experts are hopeful that more students and employees will be able to complete their vaccine series in the next few weeks.
-The 6-foot requirement remains in effect until June 1. Operations will replace signs at that time.
Section V Cleaning Facilities and Equipment – Updated to reflect changes to cleaning protocols in response to recent CDC guidance on cleaning as well as to scientific data regarding COVID-19 surface transmissions.
There are also changes to reflect current clinic screening processes (Section VIII) and international travel (Sections VII and IX), as well as a number of non-substantive changes made for clarification.
Please ensure your area’s Return to Service Plans are updated to reflect these changes.
REMINDER ON COVID-19 MITIGATION STRATEGIES IN THE RESEARCH ENVIRONMENT
With the current increase in COVID-19 cases across Oklahoma, this is a good time to do the following:
- Encourage everyone on your team to telecommute as much as possible; reducing the number of individuals in buildings and the research environment will help in reducing potential transmission of the virus.
- Follow your approved COVID-19 Standard Operating Procedures for your laboratory; be certain these are current and are posted on the lab door and inside the laboratory.
- Familiarize yourself with OU Health Sciences Center COVID-19 Resources
- Follow all masking and social distancing guidelines as described in the
OUHSC COVID-19 Return Plan (https://www.ouhsc.edu/coronavirus); wash your hands often.
- It’s a good practice to follow the HSC’s COVID-19 protocols even when you are home or in the community – masking, social distancing, and good hand hygiene help protect you, your colleagues, and your loved ones.
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( email@example.com ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
AHRQ Notice of Extension of PA-21-202 (NOT-HS-21-011)
Publication of the Revised NIH Grants Policy Statement (Rev. April 2021) for Fiscal Year 2021
Expanding Requirement for eRA Commons IDs to All Senior/Key Personnel (NOT-OD-21-109)
Notice of Pre-Application Technical Assistance Webinar for RFA-AT-21-006, "Neural Mechanisms of Force-Based Manipulations: High Priority Research Networks (U24 Clinical Trial Optional)" (NOT-AT-21-010)
Pre-Application Webinar for the Clinical Proteomic Tumor Analysis Consortium (CPTAC): RFA-CA-21-023 (U24), RFA-CA-21-024 (U24), and RFA-CA-21-025 (U01) (NOT-CA-21-072)
Continuation of Temporary Extension of Eligibility for the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) During the COVID-19 Pandemic (NOT-DE-21-003)
NIDCR Policy on Applications for Investigator-Initiated Clinical Trials (NOT-DE-21-004)
Continuation of Temporary Extension of Applicant Eligibility in PAR-19-343 "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) (NOT-GM-21-037)
Notice of Pre-Application Technical Assistance Webinar for RFA-MD-21-004, Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional) (NOT-MD-21-018)
Notice of Intent to Reissue PAR-18-845 Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed) and PAR-18-846 (R21 - Clinical Trial Not Allowed) as a Notice of Special Interest (NOSI) (NOT-OD-21-113)
Notice of Intent to Reissue PAR-18-847 Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01- Clinical Trial Optional) and PAR-18-848 (R21 - Clinical Trial Optional) as a Notice of Special Interest (NOSI) (NOT-OD-21-114)
Notice of Pre-Application Webinar for Phase II of the RADxSM-UP Initiative (NOT-OD-21-115)
Request for Information (RFI): Seeking Stakeholder Input on Enhancing Cancer Health Disparities Research (NOT-CA-21-066)
Request for Information (RFI) on Enhancing the Science for the Environmental Influences on Child Health Outcomes (ECHO) Program (NOT-OD-21-108)
Notice of NIAMS Participation in PAR-19-343, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)" (NOT-AR-21-020)
Notice of Change to NOT-OD-21-087, Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being (NOT-CA-21-065)
Notice of Change to PAR-20-238, "Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)" (NOT-DA-21-037)
Notice of Change to PAR-20-214, "Research to Improve Native American Health (R21 Clinical Trials Optional)" (NOT-DA-21-038)
Notice of Requirement for Submission of Current and Pending Support Information for the PD(s)/PI(s) of PAR-20-115 Limited Competition: Centers of Biomedical Research Excellence (COBRE) Phase 3 - Transitional Centers (P30)" (NOT-GM-21-038)
Notice of Requirement for Submission of Current and Pending Support Information in PAR-19-313 Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional) (NOT-GM-21-039)
Notice of Requirement for Submission of Current and Pending Support Information in PAR-19-312 Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 Clinical Trial Optional) (NOT-GM-21-045)
Notice of Additional Information for PAR-20-101, Genomic Expert Curation Panels (U24 Clinical Trial Not Allowed) (NOT-HD-21-028)
Notice of Early Termination of PAR-21-162, Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) (NOT-NS-21-056)
Notice of Early Termination of PAR-21-152, NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed). (NOT-NS-21-060)
Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Research Project Sites (U01) (NOT-AA-21-016)
Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24) (NOT-AA-21-017)
Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24) (NOT-AA-21-018)
Notice of Intent to Publish a Funding Opportunity Announcement for Translational and Basic Science Research in Early Lesions (TBEL) (U54 Clinical Trial Not Allowed) (NOT-CA-21-060)
Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions (TBEL) (U24 Clinical Trial Not Allowed) (NOT-CA-21-061)
Notice of Intent to Publish a Funding Opportunity Announcement for Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) (NOT-CA-21-068)
Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for Canine Cancer Immunotherapy Network (K9CIN; U24 Clinical Trial Not Allowed) (NOT-CA-21-069)
Notice of Special Interest (NOSI): Availability of Funds to defray Childcare Costs for NCI, NIA, NIDCR, NIDDK, and NIH Blueprint Predoctoral to Postdoctoral Fellow Transition Programs F99 Awardees (NOT-CA-21-053)
Notice of Special Interest (NOSI): Administrative Supplements to Stimulate and Strengthen Global Cancer Survivorship Research (NOT-CA-21-058)
Notice of Special Interest (NOSI): Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (NOT-DA-21-012)
Notice of Special Interest (NOSI): Administrative Supplements to Promote Diversity for NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Awardees (NOT-NS-21-047)
Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Support Career Enhancement Related to Clinical Research on Pain (Admin Supp Clinical Trial Not Allowed) (NOT-NS-21-048)
Please Note: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at NICHD Small Research Grant Program (R03 Clinical Trial Required) (PA-21-221) – Deadline June 16, 2021 and October 16, 2021
NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)(PA-21-231) – Deadline June 16, 2021 and October 16, 2021
NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed) (PAR-21-209) - Deadline July 27, 2021
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) (PAR-21-233) - Deadline August 10, 2021 and February 9, 2022
NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed) (PAR-21-234) – Deadline June 12, 2021
Centers for HIV Structural Biology (U54 Clinical Trial Not Allowed) (RFA-AI-21-030) – Deadline October 13, 2021
Kidney Precision Medicine Project Recruitment Sites (U01 Clinical Trial Not Allowed) (RFA-DK-20-026) - Deadline September 23, 2021
Kidney Precision Medicine Project Kidney Tissue Atlas Coordinating Center (U01 Clinical Trial Not Allowed) (RFA-DK-20-027) - Deadline September 23, 2021
Kidney Precision Medicine Project Tissue Interrogation Sites (U01 Clinical Trial Not Allowed)
(RFA-DK-20-028) - Deadline September 23, 2021
Kidney Precision Medicine Project Central Hub (U24 Clinical Trial Not Allowed) (RFA-DK-20-029)
Deadline September 23, 2021
Developmental Mechanisms of Human Structural Birth Defects (P01 Clinical Trial Not Allowed)
(RFA-HD-22-004) - Deadline July 29, 2021
Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)
(RFA-MH-21-230) - Deadline July 1, 2021 and March 1, 2021
NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN)
Award (F99/K00 Clinical Trial Not Allowed) (RFA-NS-21-012) - Deadline December 15, 2021 and April 15, 2022
OTHER FEDERAL DEADLINES
Center for Disease Control and Prevention (CDC) – Field Epidemiology Training Program (FETP) – Deadline May 26, 2021
Department of Defense (DOD) – Kidney Cancer Research Program (KCRP) – Concept Award – Required PreApplication due June 22, 2021
DOD – KCRP – Idea Development Award – Required PreApplication due June 15, 2021
DOD – KCRP – Postdoctoral and Clinical Fellowship Award – Required PreApplication due June 22, 2021
DOD – KCRP – Translational Research Partnership Award – Required PreApplication due June 15, 2021
DOD – Lupus Research Program (LRP) – Idea Award – Preapplication due August 24, 2021
DOD – LRP – Impact Award – Preapplication due August 24, 2021
DOD – LRP – Transformation Vision Award – Preapplication due August 24, 2021
Environmental Protection Agency (EPA) – Office of Research and Development – Exposure Pathway Modeling Fellowship – Rolling Deadline
U.S. Department of Energy (DOE) Office of Technology (OTT) Entrepreneurship Program – Deadline May 10, 2021